Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Immutep Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MEDIA RELEASE THE PIVOTAL TACTI-004 PHASE III TRIAL IN FIRST LINE NON-SMALL CELL LUNG CANCER (1L NSCLC) CONTINUES TO BUILD MOMENTUM AND IS RECRUITING PATIENTS AT A GROWING NUMBER OF ACTIVATED CLINICAL SITES AND COUNTRIES TRIAL-IN-PROGRESS POSTER FOR TACTI-004 PRESENTED AT THE 2025 AMERICAN SOCIETY FOR CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING NOVEL COMBINATION OF EFTI WITH KEYTRUDA (PEMBROLIZUMAB) AND CHEMOTHERAPY IN INSIGHT-003 TRIAL ACHIEVES HIGH RESPONSE RATE OF 60.8% AND 90.2% DISEASE CONTROL RATE (N=51) IN 1L NSCLC IN HIGH UNMET NEED PATIENTS WITH TPS

IMMUTEP QUARTERLY ACTIVITIES REPORT Q4 FY25

SYDNEY, AUSTRALIA, JULY 29, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (IMMUTEP OR THE COMPANY), A LATE-STAGE IMMUNOTHERAPY COMPANY TARGETING CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCES AN UPCOMING POSTER PRESENTATION FOR THE PIVOTAL TACTI-004 (KEYNOTE-F91) PHASE III TRIAL AT THE IASLC 2025 WORLD CONFERENCE ON LUNG CANCER (WCLC), TAKING PLACE IN BARCELONA, SPAIN, FROM 6-9 SEPTEMBER 2025.

IMMUTEP TO PRESENT PIVOTAL TACTI-004 TRIAL IN PROGRESS POSTER AT THE 2025 WORLD CONFERENCE ON LUNG CANCER

SYDNEY, AUSTRALIA, MAY 27, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (IMMUTEP OR THE COMPANY), A LATE-STAGE IMMUNOTHERAPY COMPANY TARGETING CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCES THE INVESTIGATOR-INITIATED EFTISARC-NEO PHASE II TRIAL EVALUATING EFTILAGIMOD ALFA (EFTI) WITH RADIOTHERAPY PLUS KEYTRUDA (PEMBROLIZUMAB) IN THE NEOADJUVANT SETTING FOR RESECTABLE SOFT TISSUE SARCOMA (STS) HAS MET ITS PRIMARY ENDPOINT. THE NOVEL COMBINATION SIGNIFICANTLY EXCEEDED THE STUDY'S PRESPECIFIED MEDIAN OF 35% TUMOUR HYALINIZATION/FIBROSIS VERSUS 15% FOR HISTORICAL DATA FROM RADIOTHERAPY ALONE IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA (STS).

IMMUTEP'S EFTI WITH RADIOTHERAPY & KEYTRUDA (PEMBROLIZUMAB) MEETS PRIMARY ENDPOINT IN PHASE II FOR SOFT TISSUE SARCOMA

SYDNEY, AUSTRALIA , APRIL 02, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (IMMUTEP OR THE COMPANY), A LATE-STAGE IMMUNOTHERAPY COMPANY TARGETING CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCES ITS MANAGEMENT WILL PRESENT AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

IMMUTEP TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

MEDIA RELEASE MARKING IMMUTEP'S TRANSITION TO A PHASE III BIOTECH, THE COMPANY'S PIVOTAL TACTI-004 TRIAL IN FIRST-LINE NON-SMALL CELL LUNG CANCER (1L NSCLC) RECEIVED FIRST REGULATORY APPROVAL MATURE DATA FROM INSIGHT-003 IN 1L NSCLC DEMONSTRATES AN EXCELLENT 32.9-MONTH MEDIAN OVERALL SURVIVAL (OS) AND 81.0% 24-MONTH OS RATE, SIGNIFICANTLY OUTPERFORMING HISTORICAL CONTROLS PROMISING NEW RESULTS IN FIRST LINE HEAD & NECK CANCER WITH PD-L1 CPS

IMMUTEP QUARTERLY ACTIVITIES REPORT Q2 FY25

SYDNEY, AUSTRALIA, DEC. 17, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMUTEP OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL LAG-3 IMMUNOTHERAPIES FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCES FAVOURABLE INITIAL SAFETY DATA FROM THE PLACEBO-CONTROLLED, DOUBLE-BLIND FIRST-IN-HUMAN PHASE I STUDY EVALUATING IMP761. THROUGH THE FIRST THREE OF FIVE SINGLE ASCENDING DOSE COHORTS IN HEALTHY PARTICIPANTS, THERE HAVE BEEN NO TREATMENT RELATED ADVERSE EVENTS.

IMMUTEP ANNOUNCES INITIAL SAFETY DATA FROM FIRST-IN-HUMAN PHASE I TRIAL EVALUATING IMP761

SYDNEY, AUSTRALIA, DEC. 12, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMUTEP OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL LAG-3 IMMUNOTHERAPIES FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCES POSITIVE CLINICAL RESULTS FROM COHORT B OF THE TACTI-003 (KEYNOTE-C34) PHASE IIB TRIAL. THIS STUDY EVALUATES EFTILAGIMOD ALPHA (EFTI) IN COMBINATION WITH MSD'S (MERCK & CO., INC., RAHWAY, NJ, USA) ANTI-PD-1 THERAPY KEYTRUDA (PEMBROLIZUMAB) IN FIRST LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (1L HNSCC) PATIENTS WITH NEGATIVE PD-L1 EXPRESSION.

IMMUTEP REPORTS PROMISING NEW DATA IN HEAD AND NECK CANCER AT ESMO IMMUNO-ONCOLOGY 2024

MEDIA RELEASE MATURE DATA IN PATIENTS WITH A MINIMUM FOLLOW-UP OF 22 MONTHS (N=21) SHOWS EXCELLENT RESULTS, WELL ABOVE HISTORICAL CONTROLS AND EXCEEDING EXPECTATIONS: MEDIAN OVERALL SURVIVAL IS 32.9 MONTHS, WITH MEDIAN PROGRESSION FREE SURVIVAL REACHING 12.7 MONTHS, AND A 24-MONTH OVERALL SURVIVAL RATE OF 81.0% DATA FROM ALL EVALUABLE PATIENTS TO DATE (N=40) DEMONSTRATES SIGNIFICANT IMPROVEMENT OF OVERALL RESPONSE RATE COMPARED TO HISTORICAL CONTROLS SAFETY CONTINUES TO BE FAVOURABLE WITH NO NEW SAFETY SIGNALS INSIGHT-003, WHICH IS NEARING COMPLETION OF ENROLMENT, EVALUATES EFTI WITH THE MOST WIDELY USED IMMUNOTHERAPY-CHEMO COMBINATION TODAY IN A SIMILAR POPULATION TO UPCOMING TACTI-004 PHASE III TRIAL SYDNEY, AUSTRALIA, NOV. 14, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (IMMUTEP OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL LAG-3 IMMUNOTHERAPIES FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCES POSITIVE DATA FROM THE INVESTIGATOR-INITIATED INSIGHT-003 PHASE I TRIAL EVALUATING EFTILAGIMOD ALPHA (EFTI) IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) AND CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (1L NSCLC) PATIENTS. PROF. DR. SALAH-EDDIN AL-BATRANOF THE FRANKFURT INSTITUTE OF CLINICAL CANCER RESEARCH (IKF) AND PROJECT LEAD STATED, THE STRENGTH OF THESE MATURE SURVIVAL RESULTS COUPLED WITH A FAVOURABLE SAFETY PROFILE IN FIRST-LINE TREATMENT OF PATIENTS WITH NON-SQUAMOUS NSCLC, THE VAST MAJORITY OF WHOM HAVE NEGATIVE OR LOW PD-L1 EXPRESSION, IS VERY ENCOURAGING.

IMMUTEP'S EFTI SHOWS EXCELLENT SURVIVAL DATA FROM INSIGHT-003 TRIAL IN NON-SMALL CELL LUNG CANCER

SYDNEY, AUSTRALIA, OCT. 29, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMUTEP OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL LAG-3 IMMUNOTHERAPIES FOR CANCER AND AUTOIMMUNE DISEASE, PROVIDES AN UPDATE ON ITS ACTIVITIES FOR THE QUARTER ENDED 30 SEPTEMBER 2024 (Q1 FY25).

IMMUTEP QUARTERLY ACTIVITIES REPORT Q1 FY25

MEDIA RELEASE SYDNEY, AUSTRALIA, OCT. 10, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMUTEP OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL LAG-3 IMMUNOTHERAPIES FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCES MARC VOIGT, CEO OF IMMUTEP, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE MAXIM HEALTHCARE VIRTUAL SUMMIT ON WEDNESDAY, OCTOBER 16, 2024 AT 9:30 AM ET. THE FIRESIDE CHAT WILL BE LIVE ON M-VEST.

Immutep Limited

IMMP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immutep Limited

IMMP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMMP